Raymond James Financial Inc. Sells 8,011 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Raymond James Financial Inc. reduced its stake in Medpace Holdings, Inc. by 3.4%, owning approximately $69.23 million in shares after selling 8,011 in the first quarter.
• Overall, 77.98% of Medpace's stock is owned by institutional investors, with significant increases in holdings from companies like Invesco Ltd. and Vulcan Value Partners LLC.
• Medpace reported strong earnings in its last quarter, with $3.10 EPS exceeding expectations, and expects an FY 2025 guidance of 13.760-14.53 EPS.

Raymond James Financial Inc. reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 227,200 shares of the company's stock after selling 8,011 shares during the period. Raymond James Financial Inc. owned approximately 0.79% of Medpace worth $69,226,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Whittier Trust Co. increased its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares in the last quarter. Colonial Trust Co SC increased its holdings in shares of Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after buying an additional 105 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Medpace during the first quarter worth $60,000. Assetmark Inc. increased its holdings in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after buying an additional 43 shares in the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of Medpace by 52.7% during the fourth quarter. True Wealth Design LLC now owns 258 shares of the company's stock worth $86,000 after buying an additional 89 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the transaction, the vice president directly owned 57,500 shares of the company's stock, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,450 shares of company stock worth $51,791,251. Corporate insiders own 20.30% of the company's stock.

Medpace Stock Up 2.3%

MEDP traded up $10.30 during midday trading on Friday, hitting $463.64. 328,935 shares of the company were exchanged, compared to its average volume of 424,882. The firm has a market capitalization of $13.02 billion, a P/E ratio of 34.47, a P/E/G ratio of 2.92 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The firm's 50 day moving average price is $378.86 and its 200-day moving average price is $335.05.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several research analyst reports. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and upped their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Mizuho upped their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Barclays upped their price target on shares of Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Finally, TD Cowen restated a "sell" rating and issued a $366.00 price objective (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.